DNA methylation gene-based models indicating independent poor outcome in prostate cancer

BMC Cancer

Table 2 Univariate Cox regression of 13 genes and available clinical variables

	HR^a(95% CI)	LR^bχ²	Adjusted^c P -value	Harrell’s c-index	Total No^d	Event No^e
Gleason score	2.33 (1.99, 2.73)	105.3	2.2*10^-16	0.79	367	99
Extent of disease	1.27 (1.21, 1.34)	80.1	2.2*10^-16	0.76	367	99
PSA	1.36 (1.28, 1.45)	68.9	6.3*10^-16	0.76	367	99
Age	1.04 (1.00, 1.09)	3.2	0.08	0.52	367	99
MAL	1.28 (1.17, 1.40)	25.4	2.0*10^-6	0.64	352	95
DPYS	1.20 (1.12, 1.29)	24.2	2.9*10^-6	0.65	344	95
TIG1	1.25 (1.14, 1.36)	20.9	1.4*10^-5	0.65	350	90
GSTP1	1.17 (1.08, 1.26)	16.4	1.2*10^-4	0.62	357	98
APC	1.18 (1.08, 1.29)	10.9	0.002	0.61	365	99
PDLIM4	1.16 (1.06, 1.26)	10.9	0.002	0.60	365	98
RARB	1.13 (1.04, 1.24)	7.7	0.01	0.60	351	98
SLIT2	1.17 (1.05, 1.31)	6.6	0.016	0.58	350	94
SFN	1.13 (1.02, 1.25)	5.8	0.023	0.57	363	99
CCND2	1.12 (1.02, 1.23)	5.2	0.029	0.56	364	99
HIN1	1.09 (1.01, 1.18)	5.1	0.029	0.59	350	97
HSPB1	1.12 (1.02, 1.22)	5.0	0.029	0.52	349	91
SERPINB5	0.95 (0.83, 1.08)	0.7	0.408	0.53	357	95

^aThe hazard ratios were calculated per 10 units increase in age, PSA, extent of disease and gene methylation while it is per unit increase in Gleason score, i.e. 4 through 10.
^bLR = likelihood ratio test.
^cThe Benjamin and Hochberg step-up procedure for controlling false discovery rate (FDR) was applied with FDR of 5%.
^dThe total number of patients for which DNAme was successfully measured. The clinical variables were available for all men included in the study.
^eThe number of patients for which a DNAme result was obtained and who died of prostate cancer.

ISSN: 1471-2407